• Seamless transition with experienced leader
• Driving force behind Sofra™ technology
• Focus on emerging opportunities

Noxopharm Limited (ASX:NOX) has announced the appointment of Dr Olivier Laczka as its new Chief Executive Officer with immediate effect. Dr Laczka previously served as the Chief Scientific Officer - Inflammation and has been the driving force behind the strategic development of the company's highly promising Sofra™ platform for the past several years. He is an experienced innovation leader in drug development, biopharmaceuticals, biotechnology and diagnostics. As a longstanding member of the company's leadership team, Dr Laczka's appointment ensures a seamless transition as Noxopharm focuses on the opportunities created by its Sofra technology and builds on the success of the recent HERACLES clinical trial and publication of groundbreaking research. Noxopharm Chairman Fred Bart expressed confidence in Dr Laczka's ability to deliver value for shareholders, stating that he has led the scientific team with genuine vision and energy while forming deep collaborative relationships with external partners. In his new role, Dr Laczka said he is honoured to be entrusted by the Board and will take responsibility for building the company in the best interests of shareholders, seizing the opportunities that are opening up for the Sofra technology.

Noxopharm has not provided any high-importance, price-sensitive forward-looking financial metrics in the announcement.

Noxopharm has stated that it has a real opportunity to grow by seizing the emerging opportunities for its Sofra technology platform and is focused on making the right decisions to take the company forward.